Benefit checks return in seconds and AI agents now wait on hold with payers, yet 65% of first-year prescriptions for new medicines still go unfilled. Here’s where eight access technologies help, where each still needs people, and what to ask a partner about them.

Electronic prior authorization makes submissions faster and cheaper. But in specialty programs, most of the cost shows up after the first rejection, which is why cost per patient on therapy, not cost per submission, is the number to watch.

The leading vendors for digitally -nabled patient onboarding in specialty therapeutics include CoverMyMeds, AssistRx, EVERSANA, CareMetx, Valeris, ConnectiveRx, Cardinal Health, Elusa Health, and Phil.

Automation can take cost out of prior authorization. Whether it takes cost out of your program depends on what happens after the first rejection.

Most manufacturers don't switch hub vendors because of one bad month. They switch because a pattern of small failures builds up until the cost of staying outweighs the cost of leaving. By the time that happens, months of underperformance have already eaten into the commercial value of the program.

When a pharmaceutical partner came to Elusa Health seeking a better way to support patients and providers, what began as a transitional engagement quickly evolved into a story of measurable transformation rooted in reliability, precision, and operational excellence.